Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
Citi
Fuji
Cerilliant
Fish and Richardson
Chubb
Cipla
QuintilesIMS

Generated: April 21, 2018

DrugPatentWatch Database Preview

CALCIUM GLUCEPTATE Drug Profile

« Back to Dashboard

When do Calcium Gluceptate patents expire, and what generic alternatives are available?

Calcium Gluceptate is a drug marketed by Abbott, Abraxis Pharm, and Lilly. and is included in four NDAs.

The generic ingredient in CALCIUM GLUCEPTATE is calcium gluceptate. There are two hundred and seventy-five drug master file entries for this compound. Additional details are available on the calcium gluceptate profile page.
Drug patent expirations by year for CALCIUM GLUCEPTATE
Synonyms for CALCIUM GLUCEPTATE
29039-00-7
AC1L1XXJ
Calcii glucoheptonas
Calcii glucoheptonas [INN-Latin]
Calcii glugoheptonas
calcium (2xi)-D-gluco-heptonate
calcium (2xi)-D-gluco-heptonate (1:2)
calcium (3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate
Calcium bis((2.xi.)-D-gluco-heptonate)
calcium bis[(2xi)-D-glycero-D-gulo-heptonate]
calcium bis[(2xi)-D-glycero-D-ido-heptonate]
calcium bis[(3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate]
Calcium gluceptate (TN)
Calcium gluceptate (USP)
Calcium gluceptate [USAN]
Calcium glucoheptonat
Calcium glucoheptonate
Calcium glucoheptonate (1:2)
Calcium glucoheptonate (INN)
Calcium Stanley
calcium(2+) bis((2xi)-D-gluco-heptonate)
CHEBI:3314
CHEMBL1237066
D00934
D0B8SY
DB00326
EINECS 249-383-8
FATUQANACHZLRT-KMRXSBRUSA-L
FT-0623394
glucoheptonate
Glucoheptonate de calcium
Glucoheptonate de calcium [INN-French]
Glucoheptonato calcico
Glucoheptonato calcico [INN-Spanish]
Glucoheptonic acid, calcium salt (2:1)
LS-186454

US Patents and Regulatory Information for CALCIUM GLUCEPTATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott CALCIUM GLUCEPTATE calcium gluceptate INJECTABLE;INJECTION 080001-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly CALCIUM GLUCEPTATE calcium gluceptate INJECTABLE;INJECTION 006470-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbott CALCIUM GLUCEPTATE calcium gluceptate INJECTABLE;INJECTION 083159-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abraxis Pharm CALCIUM GLUCEPTATE calcium gluceptate INJECTABLE;INJECTION 089373-001 Apr 30, 1987 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
UBS
Fish and Richardson
Queensland Health
Medtronic
Citi
Cantor Fitzgerald
Merck
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.